All News

Scale,weight

Weight Loss as a Therapeutic Goal in Psoriatic Arthritis

Antoni Chan, MD, PhD

Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.

Read Article
human figures on blue circle

IgG4: Rare, but new treatments on the horizon

Janet Pope, MD, MPH, FRCPC

IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.

Read Article

#ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Post-hoc analysis of CARE study comparing effect of Cenerimod 4mg vs. PBO Mos. 4-6: >10% improvement in alopecia w/Cenerimod Mos. 2-6: >10% improvement in mucosal ulcers w/ Cenerimod Early improvement in alopecia & ulcers w/Cenerimod Promising? #ACR25 @RheumNow Abs2440 https://t.co/mAqmIQashr

Links:

sheila RHEUMarampa ( View Tweet)
What's new in sjogren's? Promising phase III data of telitacicept (dual BLyS + APRIL neutralization) Pt in both dosing groups with decrease in ESSDAI compared to PBO but best results at higher (160mg) dose Similar rates of adverse events @RheumNow #ACR25 Abst LB11 https://t.co/r9JaVKzedH

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too. #ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4

Links:

David Liew drdavidliew ( View Tweet)
@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile #ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB

Links:

David Liew drdavidliew ( View Tweet)
Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card. We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better. #ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW

Links:

David Liew drdavidliew ( View Tweet)
IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172 https://t.co/xC3wgaN9bk

Links:

Janet Pope Janetbirdope ( View Tweet)
Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX

Links:

Richard Conway RichardPAConway ( View Tweet)
#ACR25 Abstr#LB11 2025 belongs to Sjogren! In patients with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met primary endpoint; change in ESSDAI vs PBO. ESSPRI improved too! Wow! That PBO response was a flat line! Will need Global study @RheumNow #ACRBest https://t.co/LXxpBZPCtF

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Eder et al. Deucravacitinib in PsA from POETYK-PsA stuides. Male and female patients had similar response rates at week 16. ACR 20 57% vs 51%, ACR50 27% vs 27%, ACR70 12% vs 10%, MDA 24% vs 20%. @RheumNow #ACR25 Abstr#2356 https://t.co/bImzTA7uUC

Links:

Richard Conway RichardPAConway ( View Tweet)
#ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Abstr#LB02 Is there a role for JAK-i for the treatment of IgG4-RD? Opel label RCT in China (N=58) showed NO relapse in Tofacitinib + GC taper vs GC Taper alone (54%). No serious infection. Interesting and a PBO-controlled is warranted @RheumNow https://t.co/dFvAmcGfCT

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR25 Abstr#LB01 After several smaller studies, a Multicentre, Phase 2b RCT of 152 #SLE pts in China. SRI-4 was met in IL-2 as s/c every other day for 12 wks, followed by weekly for another 12 wks vs PBO. Efficacy & T-regs expansion were dose dependent. On to Phase 3 @RheumNow https://t.co/L0rYr5D1R1

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)

CAR T flex for myositis 💪 LB14: Ongoing Phase 1 CD19 CAR T in refractory myositis ✅ Well-tolerated (low-grade CRS, transient cytopenias) 📈 11/11 improved MMT-8 (median +22 Day 85, +27 Day 169) 🔹 10/11 off myositis therapy at follow-up @RheumNow #ACR25 https://t.co/btOsIcHe0f

Links:

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Late Breaker: Phase 2 RCT of low dose IL2 in SLE Dose dependent response in SRI4 over 12 weeks & surprisingly high rates of LLDAS Too early to know if useful, but worth evaluating in a phase 3 #ACR25 @RheumNow Abstr#LB01 https://t.co/oPOLG82nwi

Links:

Mike Putman EBRheum ( View Tweet)
Late Breaker: Observational study of MEPO in EGPA 375 pts receiving MEPO had less ARF/CKD than 727 pts receiving standard of care Smallish event #'s & lots of p values... also, what about the vasculitis?!? #ACR25 @RheumNow AbstLB16 https://t.co/XwqNthfwPF

Links:

Mike Putman EBRheum ( View Tweet)
Semaglutide isn’t just for weight loss? In RA, users had 20–40% lower risk of synovitis, stiffness & swelling up to 1 year vs matched controls. GLP-1 agonists may offer anti-inflammatory benefit beyond metabolism. @RheumNow #ACR25 Abstract#2286

Jiha Lee JihaRheum ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×